Empaang Tablet 25 mg (Empagliflozin)

Adult dose

The recommended dosage of this medication is 10 mg once daily for monotherapy and in additional combination therapy with insulin or other blood glucose-lowering agents. If tolerance is excellent and further blood glucose control is needed, the dosage can be increased to 25 mg once daily. When this drug is used in combination with sulfonylureas or insulin, consideration may be given to decreasing the dosages of sulfonylureas or insulin to lower the risk of hypoglycemia. This drug

This medication should not be used in patients allergic to the active ingredient or components of this drug. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This drug is not used in patients with severely reduced renal function, specifically those with a glomerular filtration rate of less than 30 mL/min/1.73m2, terminal kidney disease, or those undergoing dialysis. This medication contains lactose; hence, patients with genetic conditions like lactose intolerance or galactose intolerance should not take it. In patients with slightly reduced kidney function, this drug should be used with caution, and dosage adjustments or discontinuation may be necessary for those with a glomerular filtration rate of less than 60 mL/min/1.73m2. Some patients with heart failure have limited experience with this drug, so caution is necessary, and it is not recommended for severe heart failure patients. When used with insulin or insulin secretagogues, there may be an increased risk of hypoglycemia, necessitating adjustment of these medications' dosages. This medication may cause adverse reactions such as hypoglycemia, urinary tract infections, genital infections, increased urination, and fluid volume reduction, so careful observation is needed if symptoms occur. Particularly, serious metabolic acidosis known as ketoacidosis may occur, so treatment should be immediately stopped, and a healthcare professional consulted if related symptoms appear. In elderly patients, especially those aged 75 and older, there is a higher risk of fluid volume loss, so careful use is required. This drug may increase the risk of severe infections like urosepsis, pyelonephritis, and perineal necrosis, so immediate hospital visits are necessary if infection symptoms appear. During treatment with this drug, it may affect the testing methods for blood sugar control, so the 1,5-AG test is not recommended for blood sugar monitoring. Women who are pregnant or planning to become pregnant should avoid taking this drug, and breastfeeding mothers should also avoid it. The safety and effectiveness in children under 18 have not been confirmed, so it should not be used in this population. No specific toxic symptoms have been reported in case of overdose, but appropriate treatment may be necessary depending on the clinical situation. This medication should be kept out of the reach of children and should not be transferred to other containers. There is a risk of hypoglycemia while driving or operating machinery, so caution is warranted. There may be interactions with this drug and other medications, so it is essential to inform healthcare providers of any other medications being taken.

Serious side effects

• Hives
• angioedema
• ketoacidosis
• urosepsis
• pyelonephritis
• perineal necrosis
• severe allergic reactions
• severe skin adverse reactions
• severe edema or urinary abnormalities
• severe allergic reactions

Mild side effects

• Hypoglycemia
• vulvovaginal candidiasis
• balanitis
• and other genital infections
• increased urination
• urinary tract infections
• fluid volume loss
• increased serum creatinine
• decreased glomerular filtration rate
• rash

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. Additionally, it is important to maintain a storage temperature between 1 degree and 30 degrees Celsius to effectively preserve the drug's efficacy and safety.

Appearance

Light yellow, convex oval film-coated tablet

Package unit

30 tablets/bottle